Acorda offloads manufacturing operations to Catalent for $70M amid latest restructuring to keep the ship afloat
Just over a year after the Supreme Court quashed any hopes Acorda had of protecting its once-lucrative multiple sclerosis drug Ampyra from cheaper knockoffs, the New York biotech continues to bleed cash. Now, as part of its third restructuring since 2017, the drugmaker is offloading one of its key assets.
As part of a sweeping overhaul Acorda will sell its manufacturing operations for Inbrija — an inhaled powder formulation of levodopa — to Catalent for $70 million in upfront cash that will save Acorda an additional $10 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.